Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566553345> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W1566553345 abstract "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory protease involved in cholesterol homeostasis by enhancing endosomal and lysosomal degradation of cell surface low-density lipoprotein receptors (LDL-R). While increased activity of PCSK9 has been associated with hypercholesterolemia and atherosclerosis, several healthy patients have also been identified with loss-of-function PCSK9 mutations and exhibit a hypocholesterolemia phenotype (and an extremely low incidence of coronary artery disease - CAD). These observations indicate that PCSK9 is an attractive target for the purpose of lowering circulating LDL-cholesterol, and therefore decreasing the potential for CAD and atherosclerosis. To date, several different strategies are being attempted to target and reduce plasma levels of PCSK9 but they are based on expensive therapies that may be utilized only by a limited number of patients. Phase 2 clinical studies utilizing monoclonal antibodies targeting PCSK9 demonstrated a reduction in LDL-c up to 70%. To reach a much broader population and design a low cost, long-term treatment, we developed a Virus-like Particle (VLP) based vaccine that targets the LDLR binding domain of PCSK9.Immunized mice (n=20) developed high-titer anti-peptide IgG responses that cross-reacted with PCSK9. Total cholesterol, free cholesterol, phospholipid and triglyceride levels were measured after the final boost. Vaccination with PCSK9-VLPs significantly reduced all four of these measures, with total cholesterol decreasing by over 30% (relative to pre-vaccination levels). We also immunized small groups (n=3) of rhesus macaques. Vaccination resulted in changes in lipoprotein profile at week 2, and decreases in TC (14.2%), ApoB (13.4%) and LDL-p (28.4%) at week 6 were observed. The PCSK9-VLP vaccine was well tolerated with no signs of overt toxicity in both species. In conclusion, these findings suggest that VLP-PCSK9 immunization may be an accessible, low cost, and effective new therapy for hypercholesterolemia and CAD." @default.
- W1566553345 created "2016-06-24" @default.
- W1566553345 creator A5011350352 @default.
- W1566553345 creator A5046608991 @default.
- W1566553345 creator A5068951391 @default.
- W1566553345 creator A5071501943 @default.
- W1566553345 creator A5075430537 @default.
- W1566553345 date "2014-11-25" @default.
- W1566553345 modified "2023-09-23" @default.
- W1566553345 title "Abstract 18960: Anti-PCSK9 VLP Immunization Reduces Cholesterol Levels in Mice and Non-human Primates" @default.
- W1566553345 hasPublicationYear "2014" @default.
- W1566553345 type Work @default.
- W1566553345 sameAs 1566553345 @default.
- W1566553345 citedByCount "0" @default.
- W1566553345 crossrefType "journal-article" @default.
- W1566553345 hasAuthorship W1566553345A5011350352 @default.
- W1566553345 hasAuthorship W1566553345A5046608991 @default.
- W1566553345 hasAuthorship W1566553345A5068951391 @default.
- W1566553345 hasAuthorship W1566553345A5071501943 @default.
- W1566553345 hasAuthorship W1566553345A5075430537 @default.
- W1566553345 hasConcept C126322002 @default.
- W1566553345 hasConcept C134018914 @default.
- W1566553345 hasConcept C203014093 @default.
- W1566553345 hasConcept C22070199 @default.
- W1566553345 hasConcept C2778163477 @default.
- W1566553345 hasConcept C2778849439 @default.
- W1566553345 hasConcept C2779120738 @default.
- W1566553345 hasConcept C2780072125 @default.
- W1566553345 hasConcept C2780948078 @default.
- W1566553345 hasConcept C2908647359 @default.
- W1566553345 hasConcept C43554185 @default.
- W1566553345 hasConcept C71924100 @default.
- W1566553345 hasConcept C99454951 @default.
- W1566553345 hasConceptScore W1566553345C126322002 @default.
- W1566553345 hasConceptScore W1566553345C134018914 @default.
- W1566553345 hasConceptScore W1566553345C203014093 @default.
- W1566553345 hasConceptScore W1566553345C22070199 @default.
- W1566553345 hasConceptScore W1566553345C2778163477 @default.
- W1566553345 hasConceptScore W1566553345C2778849439 @default.
- W1566553345 hasConceptScore W1566553345C2779120738 @default.
- W1566553345 hasConceptScore W1566553345C2780072125 @default.
- W1566553345 hasConceptScore W1566553345C2780948078 @default.
- W1566553345 hasConceptScore W1566553345C2908647359 @default.
- W1566553345 hasConceptScore W1566553345C43554185 @default.
- W1566553345 hasConceptScore W1566553345C71924100 @default.
- W1566553345 hasConceptScore W1566553345C99454951 @default.
- W1566553345 hasLocation W15665533451 @default.
- W1566553345 hasOpenAccess W1566553345 @default.
- W1566553345 hasPrimaryLocation W15665533451 @default.
- W1566553345 hasRelatedWork W2055814339 @default.
- W1566553345 hasRelatedWork W2059664120 @default.
- W1566553345 hasRelatedWork W2064328378 @default.
- W1566553345 hasRelatedWork W2086247967 @default.
- W1566553345 hasRelatedWork W2099654648 @default.
- W1566553345 hasRelatedWork W2110619762 @default.
- W1566553345 hasRelatedWork W2117900284 @default.
- W1566553345 hasRelatedWork W2152059213 @default.
- W1566553345 hasRelatedWork W2342735925 @default.
- W1566553345 hasRelatedWork W2563888771 @default.
- W1566553345 hasRelatedWork W2564443427 @default.
- W1566553345 hasRelatedWork W2586272713 @default.
- W1566553345 hasRelatedWork W2744116768 @default.
- W1566553345 hasRelatedWork W2792265256 @default.
- W1566553345 hasRelatedWork W2792390052 @default.
- W1566553345 hasRelatedWork W3044692602 @default.
- W1566553345 hasRelatedWork W3096780559 @default.
- W1566553345 hasRelatedWork W3103325438 @default.
- W1566553345 hasRelatedWork W3112395354 @default.
- W1566553345 hasRelatedWork W635875665 @default.
- W1566553345 hasVolume "130" @default.
- W1566553345 isParatext "false" @default.
- W1566553345 isRetracted "false" @default.
- W1566553345 magId "1566553345" @default.
- W1566553345 workType "article" @default.